Understanding the Effects of Migraines During Pregnancy: Insights and Management Tips

Investigating Migraines During Pregnancy and Their Health Implications

Understanding Migraines

Migraines are not merely severe headaches; they are classified as a neurological disorder involving various brain regions. While they may present symptoms similar to headaches, including mild to severe head pain, migraines can last from 4 to 72 hours. Various triggers can provoke an attack, including stress, noise, and specific scents. In women, low estrogen levels are among the most common triggers, which is why hormonal changes during menstruation, the use of oral contraceptives, pregnancy, and menopause can influence the frequency and severity of migraines.

Migraines During Pregnancy

During pregnancy, estrogen levels significantly increase—up to 100-fold—progressively rising from the first trimester to the third. Consequently, 80-90% of women report improvements in headache symptoms during this period. However, migraines may re-emerge within days to a month post-delivery due to the rapid decline in estrogen levels. A small percentage of women (4-8%) experience exacerbated migraines during pregnancy. These neurological complaints are among the most common issues reported during this time, and research indicates they can adversely affect maternal health.

Health Implications for Mothers and Infants

A recent study published in *Headache* examined the correlation between migraines during pregnancy and negative health outcomes for both mothers and their children. Researchers analyzed data from the Danish population registries, comparing 22,841 pregnant women who experienced migraines with 228,324 who did not.

The findings revealed that women suffering from migraines had higher incidences of hypertension, depression, and asthma prior to conception. Additionally, the study linked migraines to an increased risk of preeclampsia/eclampsia (high blood pressure) and miscarriage. Infants born to mothers with migraines were more likely to be delivered via cesarean section, experience preterm birth, and have low birth weight. Furthermore, these infants showed a higher likelihood of requiring neonatal ICU admission and hospitalization.

The research also indicated increased risks of febrile seizures, epilepsy, and respiratory distress syndrome in infants of mothers who experienced migraines. Notably, there was no significant difference in the risk of adverse events for women treated for migraines compared to those who were not, suggesting that the migraine condition itself is a more significant factor in health complications than the treatments used.

Considerations and Limitations

While the study underscores the detrimental effects migraines can have on maternal and child health, it is essential to note that it was observational. This means certain confounding variables, such as socioeconomic status and migraine severity, were not fully addressed. Many women manage migraines with over-the-counter medications, potentially influencing the outcomes. Additionally, factors like secondary causes of headaches—such as meningitis, caffeine withdrawal, pituitary disorders, and cerebral venous thrombosis—were not considered. The higher incidence of first-time pregnancies in the migraine group may also contribute to the observed risks.

Implications for Healthcare Practices

Given the potential negative impact of migraines during pregnancy on both mothers and children, healthcare providers should remain vigilant during routine check-ups. While many women experience milder migraines during pregnancy, it is crucial for healthcare services to monitor and support pregnant women suffering from migraines to mitigate potential health risks.

References

– Goadsby PJ, Lipton RB, Ferrari MD. Migraine–current understanding and treatment. N Engl J Med. 2002;346(4):257-270. doi:10.1056/NEJMra0109172.
– Burstein R, Noseda R, Borsook D. Migraine: multiple processes, complex pathophysiology. J Neurosci. 2015;35(17):6619-6629. doi:10.1523/JNEUROSCI.0373-15.20153.
– Todd C, Lagman-Bartolome AM, Lay C. Women and Migraine: the role of hormones. Curr Neurol Neurosci Rep. 2018;18(7):42. doi:10.1007/s11910-018-0845-3.
– Faubion SS, Batur P, Calhoun AH. Migraine throughout the female reproductive life cycle. Mayo Clinic Proceedings. 2018;93(5):639-645. doi:10.1016/j.mayocp.2017.11.027.
– Amundsen S, Nordeng H, Nezvalová-Henriksen K, Stovner LJ, Spigset O. Pharmacological treatment of migraine during pregnancy and breastfeeding. Nat Rev Neurol. 2015;11(4):209-219. doi:10.1038/nrneurol.2015.296.
– Jarvis S, Dassan P, Piercy CN. Managing migraine in pregnancy. BMJ. Published online 2018. doi:10.1136/bmj.k807.
– Wells RE, Turner DP, Lee M, Bishop L, Strauss L. Managing migraine during pregnancy and lactation. Curr Neurol Neurosci Rep. 2016;16(4):40. doi:10.1007/s11910-016-0634-9.
– Allais G, Chiarle G, Sinigaglia S, Airola G, Schiapparelli P, Benedetto C. Estrogen, migraine, and vascular risk. Neurol Sci. 2018;39(Suppl 1):11-20. doi:10.1007/s10072-018-3333-2.
– Skajaa N, Szépligeti SK, Xue F, et al. Pregnancy, birth, neonatal, and postnatal neurological outcomes after pregnancy with migraine. Headache. 2019;59(6):869-879. doi:10.1111/head.13536.